Swedish Orphan Biovitrum
293,8 SEK -1,74%3 investorer følger denne virksomhed
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Omsætning
-
EBIT %
-
P/E
39,33
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
SOBI
Daglig lav / høj pris
292 / 299,2
SEK
Markedsværdi
104,11 mia. SEK
Aktieomsætning
122,16 mio. SEK
Volumen
414 t
Finanskalender
Delårsrapport
24.10.2024
Årsrapport
05.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Investor | 34,7 % | 34,7 % |
Morgan Stanley Smith Barney | 9,9 % | 9,9 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Swedish Orphan Biovitrum AB: The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
Swedish Orphan Biovitrum AB: Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools